

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1498)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON 25 MAY 2018 AND RETIREMENT OF DIRECTOR**

Reference is made to the notice of annual general meeting (the “AGM Notice”) of PuraPharm Corporation Limited (the “Company”) dated 24 April 2018. The board of directors (the “Board”) of the Company is pleased to announce that at the annual general meeting held on Friday, 25 May 2018 (the “AGM”), all the proposed resolutions as set out in the AGM Notice were duly passed as ordinary resolutions by the shareholders of the Company by way of poll. The poll results in respect of all the resolutions proposed at the AGM were as follows:

Ordinary Resolutions		Number of votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the Company (the “Directors”) and the auditors of the Company for the year ended 31 December 2017.	145,859,388 (100%)	0 (0%)
2.	(a) To re-elect Dr. Tsoi Kam Bui, Alvin as an executive Director.	145,859,388 (100%)	0 (0%)
	(b) To re-elect Mr. Chan Kin Man, Eddie as an executive Director.	145,859,388 (100%)	0 (0%)
	(c) To re-elect Dr. Chan Kin Keung, Eugene as an independent non-executive Director.	145,859,388 (100%)	0 (0%)
	(d) To authorize the board of Directors to fix the Directors’ remuneration.	145,859,388 (100%)	0 (0%)

Ordinary Resolutions		Number of votes (%)	
		For	Against
3.	To re-appoint Ernst & Young as auditor of the Company to hold office until conclusion of the next annual general meeting and to authorize the board of Directors to fix their remuneration.	145,859,388 (100%)	0 (0%)
4.	To give a general mandate to the Directors to buyback shares of the Company not exceeding 10% of the total number of issued shares of the Company as at the date of passing of this resolution.	145,858,888 (100%)	0 (0%)
5.	To give a general mandate to the Directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of passing of this resolution.	145,331,388 (99.64%)	528,000 (0.36%)
6.	To extend the general mandate granted to the Directors to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares bought back by the Company pursuant to the mandate granted by resolution 4.	145,331,888 (99.64%)	527,500 (0.36%)

The description of the above resolutions is by way of summary only. The full text of such resolutions appears in the AGM Notice and the circular of the Company dated 24 April 2018.

As more than 50% of the votes were cast in favour of each of the resolutions, all of the above resolutions were duly passed as ordinary resolutions of the Company.

As at the date of the AGM, the total number of issued shares of the Company was 247,717,920 shares, which was the total number of shares entitling the shareholders of the Company to attend and vote for or against on all the resolutions at the AGM. There were no shares entitling the shareholders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and no shareholder of the Company was required to abstain from voting at the AGM under the Listing Rules. There were no restrictions on any shareholders casting votes on any of the proposed resolutions at the AGM. No shareholder had stated his or her intention in the circular of the Company dated 24 April 2018 to vote against or to abstain from voting on any of the resolutions at the AGM.

The Company’s Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

RETIREMENT OF DIRECTOR

The Board announces that Mr. Chan Lung Sang (“Mr. Chan”) has retired as an executive Director at the AGM in accordance with the Article 108 of the Company’s Articles of Association and did not offer himself for re-election due to his own decision to devote more time to his personal endeavours.

Mr. Chan has confirmed that he has no disagreement with the Board and there is no other matter in relation to his retirement that needs to be brought to the attention of the shareholders of the Company.

The Board would like to thank Mr. Chan for his invaluable contributions to the Company during his tenure of office.

By Order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 25 May 2018

Following the conclusion of the AGM, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie and Ms. Man Yee Wai, Viola and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.